SHR 4640

Drug Profile

SHR 4640

Alternative Names: SHR-4640

Latest Information Update: 19 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Class Small molecules; Uricosurics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout

Most Recent Events

  • 27 Jun 2017 Atridia plans a multiple dose phase I trial for Hyperuricaemia (In adults, In the elderly) in Australia (NCT03211403)
  • 11 May 2017 Phase-II clinical trials in Gout (In adults, In the elderly) in China (PO) (NCT03185793)
  • 01 Mar 2017 Jiangsu HengRui Medicine Co completes a phase I trial in Healthy volunteers in China (NCT02890966)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top